Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24963028 | 1.00 | GPR119 (0.47) | GPR119TRPV4SLC6A9CHRM2CHRM1 | |
| SCHEMBL28966508 | 0.91 | GPR119 (0.47) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL28966511 | 0.91 | GPR119 (0.47) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL28966574 | 0.91 | GPR119 (0.47) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL29165874 | 0.89 | GPR119 (0.46) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL29165872 | 0.89 | GPR119 (0.46) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL29165918 | 0.88 | GPR119 (0.44) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL29165920 | 0.88 | GPR119 (0.44) | GPR119SLC6A9CHRM2CHRM1CHRM3 | |
| SCHEMBL19990316 | 0.87 | GPR119 (0.48) | GPR119CHRM1CHRM3NR1H2NR1H3 | |
| SCHEMBL31087073 | 0.87 | GPR119 (0.48) | GPR119CHRM1CHRM3NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | GPR119 2414/4885TRPV4 3972/4885SLC6A9 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.